Analysis of MapLight Therapeutics' Cash Burn
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy MPLT?
Source: Yahoo Finance
- Cash Reserve Status: As of December 2025, MapLight Therapeutics holds $305 million in cash and is debt-free, providing a cash runway of approximately 2.2 years, despite an annual cash burn of $139 million, indicating the company's ability to manage funds in its early stage.
- Cash Burn Increase: Over the past year, MapLight's cash burn has surged by 74%, which may suggest accelerated business development; however, this also means a faster depletion of cash reserves, potentially impacting future fundraising capabilities.
- Market Capitalization and Fundraising Ability: With a market capitalization of $1.3 billion, MapLight's cash burn accounted for 11% of its market value last year, indicating a strong capacity to raise funds through share issuance in the coming year, albeit at the cost of shareholder dilution.
- Risk Assessment: While MapLight's cash reserve situation is reassuring, the increasing cash burn rate raises concerns about the company's future growth, prompting investors to monitor potential risk signals to make informed investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MPLT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MPLT
Wall Street analysts forecast MPLT stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.760
Low
28.00
Averages
31.00
High
34.00
Current: 29.760
Low
28.00
Averages
31.00
High
34.00
About MPLT
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of MapLight Therapeutics' Cash Burn
- Cash Reserve Status: As of December 2025, MapLight Therapeutics holds $305 million in cash and is debt-free, providing a cash runway of approximately 2.2 years, despite an annual cash burn of $139 million, indicating the company's ability to manage funds in its early stage.
- Cash Burn Increase: Over the past year, MapLight's cash burn has surged by 74%, which may suggest accelerated business development; however, this also means a faster depletion of cash reserves, potentially impacting future fundraising capabilities.
- Market Capitalization and Fundraising Ability: With a market capitalization of $1.3 billion, MapLight's cash burn accounted for 11% of its market value last year, indicating a strong capacity to raise funds through share issuance in the coming year, albeit at the cost of shareholder dilution.
- Risk Assessment: While MapLight's cash reserve situation is reassuring, the increasing cash burn rate raises concerns about the company's future growth, prompting investors to monitor potential risk signals to make informed investment decisions.
See More
MapLight Therapeutics Executive Sells Shares Amid Routine Liquidity Management
- Executive Stock Sale: Anatol Kreitzer, the Chief Discovery Officer of MapLight Therapeutics, sold 3,316 shares of common stock for approximately $88,000, reflecting a routine liquidity management strategy rather than a shift in conviction.
- Minimal Ownership Change: The sale constituted just 1% of Kreitzer's direct holdings, leaving him with 256,612 shares valued at about $6.9 million post-transaction, indicating sustained confidence in the company's prospects.
- Financial Overview: MapLight ended 2025 with $453.1 million in cash, sufficient to fund operations through 2027, despite R&D spending projected to rise to $138.3 million and quarterly net losses widening to $79.5 million.
- Clinical Trial Outlook: The company expects to complete Phase 2 enrollment for its lead schizophrenia program this month, with topline data due in Q3, and the clustering of multiple trial results could serve as significant valuation catalysts.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
MapLight Reports 2025 Financial Results and Clinical Milestones
- Increased Financial Losses: MapLight Therapeutics reported a net loss of $79.5 million for Q4 2025, significantly up from $21.2 million in the same period last year, with a total annual net loss of $161.2 million compared to $77.6 million in 2024, indicating ongoing pressure from R&D investments.
- Clinical Trial Progress: The company is advancing its ML-007C-MA drug in the ZEPHYR trial for schizophrenia, with enrollment expected to complete in April 2026 and topline results planned for Q3 2026, marking a critical milestone for future development.
- Multiple Drug Developments: MapLight is also progressing with ML-004 for autism spectrum disorder in the IRIS trial, which has completed enrollment, with topline data expected in Q3 2026, while candidate nomination for ML-055 is anticipated in 2026, showcasing the company's active pipeline across multiple R&D fronts.
- Strong Cash Position: As of 2025, MapLight holds $453.1 million in cash and investments, which is expected to fund operations through 2027, providing a financial cushion despite the losses and ensuring continued support for its R&D efforts.
See More
MapLight Therapeutics Reports Q4 Financial Results
- Earnings Report: MapLight Therapeutics reported a GAAP EPS of -$2.47 for Q4, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Reserves: As of December 31, 2025, the company had $453.1 million in cash, cash equivalents, and investments, suggesting a reasonable liquidity cushion for ongoing operations.
- Funding Outlook: Based on current operational plans and assumptions, the company expects its existing cash and investments to be sufficient to fund operations through 2027, reflecting management's confidence in future financial stability.
- Historical Financial Data: The historical earnings data for MapLight Therapeutics provides context on the company's past performance, aiding investors in assessing its long-term growth potential and associated risks.
See More
Maplight Therapeutics Inc. Reports Q4 Net Loss of $79.5 Million, Q4 EPS at -$2.47
- Financial Performance: Maplight reported a net loss of $79.5 million for Q4.
- Earnings Per Share: The company's earnings per share (EPS) for the quarter was -$2.47.
See More
Analysis of MapLight Therapeutics' Cash Burn
- Cash Reserve Status: As of December 2025, MapLight Therapeutics holds $305 million in cash and is debt-free, providing a cash runway of approximately 2.2 years, despite an annual cash burn of $139 million, indicating the company's ability to manage funds in its early stage.
- Cash Burn Increase: Over the past year, MapLight's cash burn has surged by 74%, which may suggest accelerated business development; however, this also means a faster depletion of cash reserves, potentially impacting future fundraising capabilities.
- Market Capitalization and Fundraising Ability: With a market capitalization of $1.3 billion, MapLight's cash burn accounted for 11% of its market value last year, indicating a strong capacity to raise funds through share issuance in the coming year, albeit at the cost of shareholder dilution.
- Risk Assessment: While MapLight's cash reserve situation is reassuring, the increasing cash burn rate raises concerns about the company's future growth, prompting investors to monitor potential risk signals to make informed investment decisions.
See More
MapLight Therapeutics Executive Sells Shares Amid Routine Liquidity Management
- Executive Stock Sale: Anatol Kreitzer, the Chief Discovery Officer of MapLight Therapeutics, sold 3,316 shares of common stock for approximately $88,000, reflecting a routine liquidity management strategy rather than a shift in conviction.
- Minimal Ownership Change: The sale constituted just 1% of Kreitzer's direct holdings, leaving him with 256,612 shares valued at about $6.9 million post-transaction, indicating sustained confidence in the company's prospects.
- Financial Overview: MapLight ended 2025 with $453.1 million in cash, sufficient to fund operations through 2027, despite R&D spending projected to rise to $138.3 million and quarterly net losses widening to $79.5 million.
- Clinical Trial Outlook: The company expects to complete Phase 2 enrollment for its lead schizophrenia program this month, with topline data due in Q3, and the clustering of multiple trial results could serve as significant valuation catalysts.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
MapLight Reports 2025 Financial Results and Clinical Milestones
- Increased Financial Losses: MapLight Therapeutics reported a net loss of $79.5 million for Q4 2025, significantly up from $21.2 million in the same period last year, with a total annual net loss of $161.2 million compared to $77.6 million in 2024, indicating ongoing pressure from R&D investments.
- Clinical Trial Progress: The company is advancing its ML-007C-MA drug in the ZEPHYR trial for schizophrenia, with enrollment expected to complete in April 2026 and topline results planned for Q3 2026, marking a critical milestone for future development.
- Multiple Drug Developments: MapLight is also progressing with ML-004 for autism spectrum disorder in the IRIS trial, which has completed enrollment, with topline data expected in Q3 2026, while candidate nomination for ML-055 is anticipated in 2026, showcasing the company's active pipeline across multiple R&D fronts.
- Strong Cash Position: As of 2025, MapLight holds $453.1 million in cash and investments, which is expected to fund operations through 2027, providing a financial cushion despite the losses and ensuring continued support for its R&D efforts.
See More
MapLight Therapeutics Reports Q4 Financial Results
- Earnings Report: MapLight Therapeutics reported a GAAP EPS of -$2.47 for Q4, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Reserves: As of December 31, 2025, the company had $453.1 million in cash, cash equivalents, and investments, suggesting a reasonable liquidity cushion for ongoing operations.
- Funding Outlook: Based on current operational plans and assumptions, the company expects its existing cash and investments to be sufficient to fund operations through 2027, reflecting management's confidence in future financial stability.
- Historical Financial Data: The historical earnings data for MapLight Therapeutics provides context on the company's past performance, aiding investors in assessing its long-term growth potential and associated risks.
See More
Maplight Therapeutics Inc. Reports Q4 Net Loss of $79.5 Million, Q4 EPS at -$2.47
- Financial Performance: Maplight reported a net loss of $79.5 million for Q4.
- Earnings Per Share: The company's earnings per share (EPS) for the quarter was -$2.47.
See More
